Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow QuidelOrtho Corp

Get SEC filing alerts via email and in your feed for QuidelOrtho Corp

QDEL

QuidelOrtho Corp

About QuidelOrtho Corp

QuidelOrtho Corporation specializes in developing and manufacturing diagnostic testing solutions across clinical chemistry, immunoassay, molecular diagnostics, point-of-care, and transfusion medicine segments. Its products serve healthcare providers, laboratories, blood banks, and consumers worldwide, supporting disease detection, monitoring, and blood compatibility testing. The company leverages innovative platforms, global manufacturing, and a customer-centric approach to deliver rapid, reliable, and cost-effective diagnostics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from QuidelOrtho Corp

1
1
QuidelOrtho Corp QuidelOrtho Reports 11% Revenue Decline and $91.8 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
QuidelOrtho Corp QuidelOrtho Reports $2.73 Billion Revenue for Fiscal Year 2025, 2% Decrease Due to Respiratory Product Sales Drop

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
QuidelOrtho Corp QuidelOrtho Reports 4% Revenue Decline and $733M Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
QuidelOrtho Corp QuidelOrtho Reports 4% Revenue Decline and $255.4 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
QuidelOrtho Corp QuidelOrtho Reports $692.8 Million Revenue in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
QuidelOrtho Corp QuidelOrtho Reports $2.78 Billion Revenue Decline and $2.05 Billion Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
QuidelOrtho Corp QuidelOrtho Reports Decline in Revenues and Significant Losses for Third Quarter and Nine Months Ended September 29, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments